US Guidelines Fall Short on Short-Course Tuberculosis-Preventive Therapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37879092.
- Also identified by DOI 10.1093/cid/ciad659 and PMC identifier 10954328.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The provision of tuberculosis-preventive therapy (TPT) to vulnerable populations is critical for global control. Shorter-course TPT regimens are highly effective and improve completion rates. Despite incorporation of 1 month of rifapentine and isoniazid into global guidelines, current US TPT guidelines do not include this as a recommended regimen, but should.
Medical subject headings
- Tuberculosis
- Latent Tuberculosis